Filter Results:
(89)
Show Results For
- All HBS Web
(166)
- News (48)
- Research (89)
- Events (1)
- Multimedia (6)
- Faculty Publications (54)
Show Results For
- All HBS Web
(166)
- News (48)
- Research (89)
- Events (1)
- Multimedia (6)
- Faculty Publications (54)
Page 1 of 89
Results →
Sort by
- May 2023 (Revised June 2023)
- Supplement
Novartis (C): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Testing and Trials; Health Care and Treatment; Business Model; Problems and Challenges; Pharmaceutical Industry; Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (C): Reimagining Medicine." Harvard Business School Supplement 723-445, May 2023. (Revised June 2023.)
- May 2023 (Revised June 2023)
- Supplement
Novartis (B): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Care and Treatment; Business Model; Production; Business Strategy; Pharmaceutical Industry
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (B): Reimagining Medicine." Harvard Business School Supplement 723-444, May 2023. (Revised June 2023.)
- March 2014 (Revised November 2020)
- Case
The Novartis Malaria Initiative
By: Michael Chu, Vincent Marie Dessain and Emilie Billaud
The Novartis Malaria Initiative was designed, as a result of a precedent–setting agreement with the World Health Organization in 2001, to provide a breakthrough treatment for malaria—"at no profit"—for public health systems. What had begun as an exemplary act of... View Details
Keywords: Health Care and Treatment; Product Marketing; Corporate Social Responsibility and Impact; Social Enterprise; Pharmaceutical Industry; Switzerland; Africa; Nigeria
Chu, Michael, Vincent Marie Dessain, and Emilie Billaud. "The Novartis Malaria Initiative." Harvard Business School Case 314-103, March 2014. (Revised November 2020.)
- July 1999
- Supplement
Jan Eriksson of Novartis Indonesia
By: Christopher A. Bartlett and Carin-Isabel Knoop
A follow-up interview, in Summer 1998, with the protagonist of the Novartis Indonesia case series. He describes ongoing strategy and activities. View Details
Bartlett, Christopher A., and Carin-Isabel Knoop. "Jan Eriksson of Novartis Indonesia." Harvard Business School Video Supplement 899-509, July 1999.
- May 2023 (Revised June 2023)
- Case
Novartis (A): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Care and Treatment; Business Model; Leadership; Pharmaceutical Industry; Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (A): Reimagining Medicine." Harvard Business School Case 723-443, May 2023. (Revised June 2023.)
- March 2008
- Case
Novartis AG: Science-Based Business
By: H. Kent Bowen and Courtney Purrington
Novartis is a science-based drug company, which has important implications for its business strategy. It is one of the largest pharmaceutical companies in the world with over $38B in sales in 2007. Pharmaceuticals account for slightly over $24B of that total. In 2007,... View Details
Keywords: Innovation and Invention; Resource Allocation; Product Development; Partners and Partnerships; Research and Development; Science-Based Business; Pharmaceutical Industry
Bowen, H. Kent, and Courtney Purrington. "Novartis AG: Science-Based Business." Harvard Business School Case 608-136, March 2008.
- September 2000
- Case
Novartis Agricultural Discovery Institute (A)
Steve Briggs, a PhD biologist, is asked to propose a strategy to take global life-science giant Novartis into the rapidly expanding field of plant genomics. View Details
Keywords: Design; Plant-Based Agribusiness; Genetics; Infrastructure; Biotechnology Industry; Agriculture and Agribusiness Industry
West, Jonathan, and Christian G. Kasper. "Novartis Agricultural Discovery Institute (A)." Harvard Business School Case 601-010, September 2000.
- February 1998 (Revised November 1998)
- Case
Novartis (A): Being a Global Leader
By: Srikant M. Datar and Carin-Isabel Knoop
For the Novartis leaders, the decision to "use stretch budgets again next year" highlights the tension between candor and empowerment and command-and-control, between the new and the old, between high performance and business as usual, between Ciba and Sandoz.... View Details
Keywords: Goals and Objectives; Leading Change; Organizational Culture; Performance; Budgets and Budgeting
Datar, Srikant M., and Carin-Isabel Knoop. "Novartis (A): Being a Global Leader." Harvard Business School Case 198-041, February 1998. (Revised November 1998.)
- October 2007
- Case
Valuation at Novartis
By: Paul M. Healy
Healy, Paul M. "Valuation at Novartis." Harvard Business School Case 108-041, October 2007.
- April 1998 (Revised September 1998)
- Case
Jan Eriksson at Novartis Indonesia (A)
By: Carin-Isabel Knoop and Anthony St. George
Jan Eriksson is the country manager of the Novartis AG joint venture in Indonesia. At the time of the case, Novartis is the world's largest pharmaceutical company. The case describes the steps Eriksson took to merge the Indonesian operations of Novartis' parents,... View Details
Keywords: Multinational Firms and Management; Joint Ventures; Financial Crisis; Pharmaceutical Industry; Indonesia
Knoop, Carin-Isabel, and Anthony St. George. "Jan Eriksson at Novartis Indonesia (A)." Harvard Business School Case 898-219, April 1998. (Revised September 1998.)
- November 2019
- Case
The Genesis Lab at Novartis
By: Amy C. Edmondson, Ranjay Gulati, Patrick J. Healy and Kerry Herman
Novartis' Genesis Labs program, launched in 2016 as part of Novartis Institutes for Biomedical Research (NIBR), hosted pitch competitions where teams of NIBR scientists proposed ideas to explore that aimed to revolutionize drug discovery. The goal was to break down... View Details
Keywords: Drug Discovery; Health Care and Treatment; Research and Development; Innovation and Invention; Programs; Management
Edmondson, Amy C., Ranjay Gulati, Patrick J. Healy, and Kerry Herman. "The Genesis Lab at Novartis." Harvard Business School Case 620-007, November 2019.
- April 2009 (Revised April 2009)
- Case
Immusol and Novartis
By: Regina E. Herzlinger, Keyne M. Monson, Juan D. Betancourt and Victor Li
Should Immusol strive to become a fully integrated pharmaceutical company? How should a small pharmaceutical company structure a deal for its novel technology with the giant Novartis? View Details
Keywords: Technological Innovation; Rights; Negotiation Deal; Negotiation Participants; Alliances; Pharmaceutical Industry
Herzlinger, Regina E., Keyne M. Monson, and Juan D. Betancourt. "Immusol and Novartis." Harvard Business School Case 303-038, April 2009. (Revised from original October 2002 version.)
- January 2001 (Revised May 2003)
- Case
Novartis Pharma: The Business Unit Model
By: Srikant M. Datar, Carin-Isabel Knoop and Cate Reavis
In June 2000, Novartis reorganized its pharmaceutical business to form global business units in oncology, transplantation, ophthalmology, and mature products. The remaining primary care products continued to be managed within global functions (e.g., R&D and marketing).... View Details
Keywords: Restructuring; Recruitment; Product Marketing; Organizational Structure; Problems and Challenges; Health Industry; Pharmaceutical Industry
Datar, Srikant M., Carin-Isabel Knoop, and Cate Reavis. "Novartis Pharma: The Business Unit Model." Harvard Business School Case 101-030, January 2001. (Revised May 2003.)
- February 2008 (Revised November 2008)
- Case
Global Talent Management at Novartis
By: Jordan Siegel
This case tackles the topic of global talent management. It can be used to analyze the performance measurement, incentive, and talent development system used at a major multinational company. This case can also be used to analyze the extent to which this system should... View Details
Keywords: Talent and Talent Management; Developing Countries and Economies; Multinational Firms and Management; Performance Evaluation; Motivation and Incentives; Adaptation
Siegel, Jordan. "Global Talent Management at Novartis." Harvard Business School Case 708-486, February 2008. (Revised November 2008.)
- March 2015
- Case
Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (A)
By: Gautam Mukunda, Thomas DeLong and Aldo Sesia
Over the course of a tumultuous weekend in April 2010, André Wyss was put in charge of Novartis Pharmaceuticals Corporation (NPC), the U.S. sales and marketing subsidiary of Novartis Pharma AG. He was brought in at a critical point in the organization's evolution with... View Details
Keywords: LEAD; Talent Management; Leadership And Change Management; Change Management; Organizational Change and Adaptation; Restructuring; Pharmaceutical Industry; United States
Mukunda, Gautam, Thomas DeLong, and Aldo Sesia. "Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (A)." Harvard Business School Case 415-013, March 2015.
- April 2006
- Case
Finance Leadership in Novartis Consumer Health Businesses
By: Boris Groysberg and Ingrid Vargas
Describes and contrasts the roles and challenges of three high-performing finance heads at Novartis Consumer Health businesses in Australia, Japan, and Venezuela. All three faced tremendous pressures in terms of managing time and limited resources, but the particular... View Details
Keywords: Finance; Financial Management; Multinational Firms and Management; Leadership Style; Health Industry; Japan; Australia; Venezuela
Groysberg, Boris, and Ingrid Vargas. "Finance Leadership in Novartis Consumer Health Businesses." Harvard Business School Case 406-102, April 2006.
- April 2010
- Teaching Note
Global Talent Management at Novartis (TN)
By: Jordan I. Siegel
Teaching Note for 708486. View Details
- December 1999 (Revised September 2000)
- Case
Novartis Agricultural Discovery Institute, Inc. (C)
Supplements the (A) case. View Details
West, Jonathan, and Christian G. Kasper. "Novartis Agricultural Discovery Institute, Inc. (C)." Harvard Business School Case 600-043, December 1999. (Revised September 2000.)
- April 2015
- Supplement
Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (B)
By: Gautam Mukunda, Thomas DeLong and Aldo Sesia
This (B) case describes the actions André Wyss, president of Novartis Pharmaceuticals Corporation, took in early 2012 to transform the company's General Medicines group and build its specialty medications, marketing the selling capabilities in the face of falling... View Details
Keywords: LEAD; Leadership And Change Management; Talent Management; Organizational Change and Adaptation; Leadership; Change Management; Talent and Talent Management; Pharmaceutical Industry; United States
Mukunda, Gautam, Thomas DeLong, and Aldo Sesia. "Novartis Pharmaceuticals Corp: Redefining Success in the U.S. (B)." Harvard Business School Supplement 415-049, April 2015.
- March 1999
- Case
Hans Fritz at Novartis Thailand (A): The First Month
By: Michael Y. Yoshino and Carin-Isabel Knoop
Dr. Hans Fritz is 37 years old when he arrives in Bangkok on March 1, 1998 to assume his position as general manager of Novartis Thailand. Novartis is the world's largest pharmaceutical company. He had lobbied to transition from a staff position to this line management... View Details
Keywords: Management Teams; Organizational Structure; Transition; Organizational Change and Adaptation; Working Conditions; Organizational Culture; Growth and Development Strategy; Crisis Management; Decision Making; Pharmaceutical Industry; Thailand
Yoshino, Michael Y., and Carin-Isabel Knoop. "Hans Fritz at Novartis Thailand (A): The First Month." Harvard Business School Case 399-123, March 1999.